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Background: In order to obtain a reliable 177Lu-DOTATATE therapy dosimetry, it is
crucial to acquire accurate and precise activity measurements with the radionuclide
calibrator, the SPECT/CT camera, and the NaI(Tl) well counter. The aim of this study
was to determine, in a clinical context, the accuracy and the precision of their
activity quantification over a range of activities and time.
Ninety-three 177Lu sources from the manufacturer were measured in
the radionuclide calibrator over 2.5 years to evaluate its calibration accuracy and
precision compared to the manufacturer’s value. A NEMA 2012/IEC 2008 phantom
was filled with a 177Lu activity concentration sphere-to-background ratio of five. It
was acquired with the SPECT/CT camera to determine the reconstruction parameters
offering the best compromise between partial volume effect and signal-to-noise
ratio. The calibration factor was computed accordingly. The calibration quality was
monitored over 2.5 years with 33 phantom acquisitions with activities ranging from
7040 to 0.6 MBq. Home-made sources were used to calibrate the well counter. Its
reliability was evaluated with activities ranging from 150 to 0.2 kBq measured 34
times over 2.5 years.
Results: For the radionuclide calibrator, median [interquartile range] for the error
on activity measurement was −0.99 [1.31] %. The optimal SPECT reconstruction
parameters were obtained with 16 iterations, 16 subsets and a 12-mm Gaussian
post-filter. The calibration factor was 9.87 cps/MBq with an error of −1.05 [2.12] %.
The well counter was calibrated with 31.5 cps/kBq, and the error was evaluated
to −12.89 [16.55] %.
Conclusions: The accuracy and the precision of activity quantification using
dedicated quality control were found to be sufficient for use in dosimetry
implemented in clinical routine. The proposed methodology could be implemented
in other centres to obtain reproducible 177Lu-based treatment dosimetry.
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Overexpression of somatostatin receptors, a hallmark of well differentiated metastatic
neuroendocrine tumors (NETs) [1], renders NETs susceptible to treatment with radiola-
beled synthetic somatostatin analogues. According to recently established guidelines,
peptide receptor radionuclide therapy (PRRT) consists in the systemic administration
of fixed activities of radiolabeled somatostatine analogues, usually fractionated in
sequential cycles of 6–12 weeks [2]. Third generation PRRT consists of DOTA(0),
Tyr(3)-octreotate labelled with radionuclide 177Lu (177Lu-DOTATATE) and has proven
efficacy in clinical trials [3] with a low toxicity profile.
177Lu represents an interesting therapeutic radionuclide with a physical half-life of
6.647 days and a combined electron and photon emission. 177Lu has a 100% probability of
decaying via electron emission to three excited levels of 177Hf. The most abundant electrons
have a maximum energy of 177, 385 and 498 keV and an emission probability of 11.58, 9.1,
and 79.3%, respectively [4, 5]. The high energy transfer and the short track of these electrons
enable 177Lu to be used in molecular radiotherapy of metastatic cancer. In addition, the
transitions from the three excited levels of 177Hf to its ground state occur via six gamma
photon emissions. The two most abundant photons have energies of 112.95 and 208.37 keV
with 6.17 and 10.36% probability of emission, respectively [4, 5]. These photons can be used
for imaging on a SPECTcamera which offers unique dosimetry possibilities.
Understanding the correlation between the tumor cumulative absorbed dose and
tumor response is crucial for the optimization of PRRT outcome. The absorbed dose to
the tumor is restricted by the maximum acceptable absorbed dose to the kidneys and
bone marrow (i.e., the therapy critical organs), hence limiting the total number of ad-
ministered cycles. A reliable dosimetry method is thus mandatory in order to improve
the efficacy/toxicity balance and achieve patient-specific treatment planning. More spe-
cifically, pre- and peri-therapeutic dosimetry might help us gain better knowledge of
PRRT therapeutic window, hence, allowing the prediction of the maximal absorbed
dose to the tumors while minimizing radiation burden to the critical organs.
In order to achieve a reliable dosimetry, accurate and precise activity quantification is
required. Quantitative data suitable as inputs for dosimetry are obtained through differ-
ent measuring devices: the radionuclide calibrator to measure the administered activity,
the SPECT/CT camera to acquire images of the radiopharmaceutical distribution, and
the NaI(Tl) well counter to quantify activity in blood samples over time. In the last dec-
ade, optimization of acquisition and reconstruction parameters for 177Lu quantitative
SPECT imaging have been extensively studied in order to improve the absorbed dose
computation reliability [6–10]. The other aforementioned measuring devices, though
also involved in PRRT dosimetry, were often overlooked.
The aim of this work was to determine, in a clinical context, the accuracy and
the precision of all activity quantification methods in order to develop a reliable
177Lu-DOTATATE dosimetry. The first objective was to determine the most adequate
parameters for 177Lu activity measurement with the radionuclide calibrator, the well
counter and the SPECT/CT camera used in clinical routine. The second objective was to
determine a calibration factor (CF) to convert counts to becquerels for each device.
Finally, dedicated quality control steps were developed to evaluate the accuracy and the
precision of the established CFs for the chosen measurement parameters with respect to
manufacturer maintenance, time, and range of activities.
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For the radionuclide calibrator and the SPECT/CT camera, the standard quality
controls were performed according to national guidelines (i.e., Federal Agency for
Nuclear Control recommendations, already available from 2008 and transposed into
Belgian law on March 15, 2016).
Based on the given manufacturer’s specifications (ITG, Isotope Technologies
Garching GmbH), non-carrier added 177Lu had an activity measurement error maximum
of 5%, a radionuclide purity above 99.9% with a 177mLu/177Lu ratio lower than 10−7.Radionuclide calibrator
Description
All prepared activities were measured with a radionuclide calibrator CRC-15R (Capin-
tec; manufactured in 1990) with an ionization chamber well of 6 cm diameter and
26 cm depth. 177Lu vials were put at the bottom of the dedicated syringe holder raised
at 3 cm relative to its normal position in order to place the vials closer to the area of
highest sensitivity.
Calibration with 177Lu
The radionuclide calibrator was calibrated for 177Lu with a vial from ITG with a total
amount of activity of 15.3 GBq as measured by the manufacturer. The CF was then
adjusted to reach the expected activity decay-corrected at the time of measurement.
Quality control
A specific quality control related to 177Lu was implemented to evaluate the validity and
control the constancy of the CF: the activity measured by the manufacturer was
compared to the on-site measurement for each received 177Lu ITG vial.SPECT/CT camera
Description
All acquisitions were performed on a hybrid dual head SPECT/CT camera (Symbia
TruePoint T, Siemens Healthcare; manufactured in 2008) with a 9.5 mm NaI(Tl) crystal
thickness and a rectangular field of view of 537 × 383 mm2. The acquisitions were all
performed with the parallel-hole medium energy, low penetration (MELP) collimator in
non-circular (auto-contour) step-and-shoot mode. 32 frames (180°) of 40 s were
acquired by each head; the time per frame was doubled for very low count rates (i.e.,
lower than 20 kBq/mL for the phantoms and for the last SPECT/CT acquisition at 168 h
post-injection for the patients). One photopeak energy window centred on 208 keV and
one lower scatter window were used, their widths were 20% [187.56–229.24 keV] and 10%
[166.72–187.56 keV] of the energy peak, respectively (Fig. 1). The SPECT acquisition was
followed by a CT scan. The parameters of the tube were a voltage of 130 kV and an
effective current-time product of 40 mAs (CareDose, Siemens Healthcare). CT data were
reconstructed to 512 × 512 matrix with 0.98 × 0.98 mm2 pixel size and a slice thickness of
5 mm. Out of the three CT reconstruction filters available on the Symbia Truepoint T
and dedicated to body (B) image acquired with standard (s) scan mode (z-flying focal spot
technology without hultrahigh resolution comb filter) (B08s, B30s and B60s), two were
selected, namely, B08s and B30s. The very large smoothing filter B08s was used for
Fig. 1 177Lu energy spectrum acquired on SPECT/CT camera. Four energy windows were defined but only
the 208 keV photopeak window A (20% width [187.56–229.24 keV]) and the lower scatter window B
(10% width [166.72–187.56 keV]) were used
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tion in soft tissue.
Reconstruction of the data was carried out with the software from the camera manu-
facturer (Syngo MI Applications version 8.5, Siemens Healthcare). A SPECT matrix
size of 128 × 128 was used with a voxel size of 4.8 × 4.8 × 4.8 mm3. For SPECT data, the
proprietary iterative (ordered subset expectation maximization or OSEM) reconstruc-
tion algorithm with collimator depth-dependent three-dimensional resolution recovery
(Flash 3D, Siemens Healthcare) was chosen. No pre-filtering of the images was applied.
CT based AC and dual energy window (DEW) scatter correction (SC) were used but
no additional partial volume effect correction was performed. The SC was performed
as follows:
Csc corrected ¼ CPh−k  CLW
with Csc corrected the number of counts after SC, CPh the number of counts in the
photopeak window, CLW the number of counts in the lower scatter window and k a
scaling factor (equal to 1 in this study).
The determination of the number of iterations, the number of subsets, and the size
of the Gaussian post-filter for OSEM reconstruction was based on a phantom study.
The NEMA 2012/IEC 2008 PET body phantom was used (Fig. 2). The main compart-
ment and the spheres (10, 13, 17, 22, 28, and 37 mm diameter) were filled with 193
and 1012 kBq/mL of 177Lu, respectively, to mimic the typical contrast between the liver
and the hepatic lesions in patients treated with 177Lu-DOTATATE. The central cylinder
was filled with air. The phantom was acquired with the previously defined parameters.
The images were then reconstructed with a Gaussian post-filter with a full width at half
maximum (FWHM) of 0, 4.8, 9.6, 12, and 14.4 mm and with a product of iterations (i)
and subsets (s) equal to 4i × 8s, 8i × 8s, 8i × 16s, and 16i × 16s. With PMOD software
(PMOD biomedical image quantification version 3.6), six cylindrical VOIs (212 mL
each) were drawn in the main compartment, and six spheres were defined according to
their theoretical dimensions and positions (Fig. 2). The noise in the homogeneous area
Fig. 2 a NEMA 2012/IEC 2008 phantom. b Six cylindrical VOIs (green) were defined in the main compartment
of the NEMA phantom on SPECT/CT images for the SPECT CF computation; for the reconstruction parameter
determination, six spherical VOIs (blue) were added. c Photograph and SPECT/CT image of the plastic bottle
used for the CF quality control
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The partial volume effect on activity quantification in small areas was assessed by
means of the activity concentration ratio between the 22 and the 37 mm spheres.
Taking into account that a large number of iterations and subsets with a small filter
decreases the partial volume effect but increases the noise, several sets of parameters
offered a good compromise between both resolution and noise. The optimal parameters
were chosen by way of visual assessment of the reconstructed phantom images by a
blinded expert nuclear medicine physician.
This phantom and the others presented in this study were all prepared with addition
of an excess of ethylenediaminetetraacetic acid (EDTA) to prevent 177Lu from sticking
to the phantom walls. The syringes used to fill the phantoms were systematically
measured in the radionuclide calibrator before 177Lu injection in the phantom and
afterwards to compute the exact amount of injected activity. The phantoms were
shaken before each acquisition to prevent 177Lu from sedimenting. All the measure-
ment and acquisition dates and times were carefully reported.
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For the determination of the CF for SPECT images with 177Lu, the NEMA 2012/IEC
2008 PET body phantom was used (Fig. 2). The main compartment, the central
cylinder, and the spheres were filled with 686, 1010, and 1668 kBq/mL, respectively.
The approximate total amount of 177Lu activity in the phantom was 7040 MBq, which
is close to the activity injected to the patients for therapy. The phantom was acquired
at ten time-points during 1.5 months. Six cylindrical VOIs (212 mL) were distributed
in the main compartment on each SPECT/CT acquisition (Fig. 2).
For each VOI, the CF expressed in (cps/voxel)/(MBq/ml) was then computed as
follows:
CF ¼ cmes
T acq  Cprep  exp − ln2ΔtT1=2
 
With cmes the mean number of counts per voxel, Tacq the acquisition duration (i.e.,
time per frame multiplied by total number of frames), Cprep the prepared activity
concentration, Δt the time between the phantom preparation and the acquisition, and
T1/2 the physical half-life of the radionuclide. To be more easily compared with other
studies, the voxel size was taken into account: after multiplying the previous CF by the
number of voxels per mL, the CF was expressed in cps/MBq. The final CF was
computed by averaging the 60 computed CFs (6 cylindrical VOIs × 10 acquisitions).Quality control
Some specific quality controls related to the SPECT CF were developed to evaluate its
stability over time and range of activities and determine the influence of manufacturer
maintenance. For this purpose, a phantom was filled with 177Lu every 9 months
(Table 1). This procedure was simplified by using a less complex phantom consisting of
a 6.5 × 6.5 × 15 cm3 plastic bottle (Fig. 2). The exact volume in the bottle was obtained
by weighing before and after filling with water. The NEMA phantom was used for the
last verification in March 2016. The phantoms were acquired multiple times on the
SPECT/CT camera during more than 1 month to cover a large range of activities. The
first phantom was acquired twice on the same day, before and after a complete tuning
of the photomultipliers to evaluate the impact on the quantification. For each acquisi-
tion, a large box was drawn with PMOD around the bottle or in the main compartment
of the NEMA phantom. The measured activity was computed with the determined CF.Table 1 Characteristics of 177Lu phantoms acquired on SPECT/CT camera to check for CF stability
over time and range of activities
Phantom type Bottle NEMA
Phantom preparation date Mar 2014 Dec 2014 Oct 2015 Mar 2016
Activity at first acquisition [MBq] 600 530 330 1926
Activity at last acquisition [MBq] 17 2 0.6 37
Activity concentration at first acquisition [kBq/ml] 933 815 526 174
Activity concentration at last acquisition [kBq/ml] 27 3 1 3
Delay between first and last acquisition [days] 34 55 60 38
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radionuclide calibrator measurement corrected for physical decay.
NaI(Tl) well counter
Description
The measurement of the activity in samples was performed with a well counter 2480
WIZARD2 (Perkin Elmer; manufactured in 2011) with a single 7.5 cm diameter NaI(Tl)
crystal well and a solid lead shield of 7.5 cm. Standard tubes (7.5 cm height × 1.2 cm
diameter; 8 mL volume) were filled with 200 μL of 177Lu solution and counted for
20 min in the well counter. The measurement duration was chosen in order to reach
an acceptable statistical error (<1%) with a total number of counts higher than 10,000
in the photopeak for samples with the lowest activity. Background was measured daily
and subtracted from the measurement [11]. No dead-time correction was applied.
The quantification was made by summing the number of counts detected in the
208 keV photopeak of the 177Lu with an energy window width of 20% of the energy of
the peak as recommended by Zanzonico [12]. Raw data from the well counter (Fig. 3)
were directly used to avoid spectrum modifications from the software part (peak pos-
ition adjustment, energy spectrum resampling).
Calibration with 177Lu
The determination of a CF for the gamma counter was investigated. Standard tubes
were filled with 200 μL of different amounts of 177Lu activities: six tubes were prepared
with 130 kBq, two with 30 kBq, and three with 3 kBq. They were obtained with succes-
sive dilutions from a vial containing a known activity concentration of 177Lu: the
volume was determined by measuring the weight of the vial before and after filling, and
the activity was measured in the radionuclide calibrator. The 11 samples were mea-
sured eight times during 1.5 months, covering activities ranging from 130 to 0.15 kBq.
For each measurement, the CF expressed in cps/kBq was then computed as follows:
CF ¼ cmes
T acq  Aprep  exp − ln2ΔtT1=2
 Fig. 3 177Lu raw energy spectrum acquired on NaI(Tl) well counter. One energy window was defined
around 208 keV photopeak (20% width)
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tion duration, Aprep the prepared activity, Δt the time between the sample preparation
and the acquisition, and T1/2 the physical half-life of the radionuclide. The final CF was
obtained by computing the weighted mean value for the three groups of computed CFs
((6 + 2 + 3) samples × 8 measurements).
Quality control
The well counter sensitivity and the position of a reference energy peak were controlled
monthly [11] with standard calibrated sources of 129I and 137Cs. Their main energy
peaks (i.e., 40 and 662 keV, respectively) allowed checking the stability of the well
counter over time for a large range of energies.
Specific quality controls were developed to evaluate the stability of the CF for 177Lu
measurements over preparations and range of activities. For each patient treatment, the
177Lu-DOTATATE synthesis resulted in a vial containing 20 mL of radiopeptide. The
activity in the vial was measured in the radionuclide calibrator, and the amount of
activity needed for the patient treatment was adjusted by extracting a known volume
from the vial with a syringe. For 34 treatments, a 200 μL sample with approximately
100 kBq was taken from the syringe containing a known activity concentration. The
error was evaluated by comparing the well counter measured activity to the expected
activity based on the radionuclide calibrator measurement corrected for physical decay.
Finally, among the 34 prepared samples, seven were measured five times during
2 months. Based on the established CF, their activities were computed over time. These
results were corrected for physical decay and normalized by the mean value for each
sample. It allowed evaluating the stability of the well counter over activities ranging
from 120 to 0.2 kBq.Statistical analysis
Descriptive statistics are presented as median interquartile range½  . On the one hand,
the median value conveys the systematic error committed on activity quantification and
the accuracy of the measurement compared to a reference. On the other hand, the
interquartile range characterizes the random errors committed on activity quantifica-
tion and the precision of the measurement. When box-and-whisker plots are used, the
points outside the whiskers are mild outliers defined as values beyond Q1 − 1.5 × IQ
and Q3 + 1.5 × IQ with Q1 and Q3 the first and third quartile of the considered
distribution and IQ =Q3 −Q1 the interquartile range. Median and interquartile range
are computed on all available data: the size of the considered population or sample is
always referred to as N.Results
Radionuclide calibrator
Based on the first ITG vial measurement, the CF was set to 150 × 10 for the CRC-15R
radionuclide calibrator. 150 was the radionuclide calibrator dial setting for the 177Lu,
and the readout had to be multiplied by a factor of 10 to obtain the activity value [13].
This factor was never modified. According to the specific implemented quality con-
trol, 93 vials were measured in total over 2.5 years. The systematic and random
Marin et al. EJNMMI Physics  (2017) 4:7 Page 9 of 15differences between the activity measured by the manufacturer and the on-site
measurement were −0.99 [1.31] % (N = 93).SPECT/CT camera
The CoV in the main compartment of the NEMA phantom and the partial volume
effect on the spheres for different reconstruction parameters are presented in Fig. 4.
The activity quantification ratio between the 22 and the 37 mm spheres was improved
with the increasing number of iterations and subsets and decreasing filter size. The
noise increased more rapidly with the increasing number of iterations and subsets for
0 and 4.8 mm filters. The best compromise corresponded to the maximum number of
iterations and subsets (16i × 16s) with a 9.6-mm filter. Ultimately, after visual assess-
ment of the reconstructed phantom images by the blinded expert nuclear medicine
physician, the optimal parameters selected were the maximum number of iterations
and subsets (16i × 16s) but with a 12-mm filter. Consequently, the later was used in
future image reconstruction.
The use of six VOIs in the main compartment of the NEMA phantom
highlighted the importance of VOI location: the mean number of counts detected
in the upper part of the phantom was systematically lower than in the bottom
(Fig. 5). The final CF was set to 1.09 (cps/voxel)/(MBq/mL) by computing the
mean value of the 60 calculated CFs (i.e., 6 VOIs × 10 acquisitions). For ease of
comparison, this factor can also be expressed as 9.87 cps/MBq (N = 60), which is
independent of the pixel size.
For activity concentrations and activities ranging from 933 to 20 kBq/mL and
from 1926 to 13 MBq respectively, the systematic and random errors committed
on activity quantification were evaluated to −1.05 [2.12] % (N = 33) over 2.5 years
when using the established CF (Fig. 6). For activity concentrations and activities
lower than 20 kBq/mL and 13 MBq, respectively, the measurements highlighted an
activity overestimation up to 30% (Fig. 6). Finally, one phantom acquired before
and after the photomultipliers tuning on March 2014 showed a difference of 2.3%
in the CF error.Fig. 4 (left) The CoV in the main compartment of the NEMA phantom and (right) the activity concentration
ratio between the 22 and the 37-mm spheres of the NEMA phantom on 177Lu SPECT/CT images with 0, 4.8,
9.6, 12, and, 14.4-mm filters and with 4i × 8s, 8i × 8s, 8i × 16s, and 16i × 16s
Fig. 5 Computed SPECT CF for 177Lu activity concentrations and activities ranging from 686 to 8 kBq/ml
and from 7040 to 80 MBq, respectively, (10 acquisitions) with 6 cylindrical VOIs equally distributed in lower,
middle, and upper part of the NEMA phantom; the mean computed CF (red line)
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The CF for the well counter was set to 31.5 cps/kBq by computing the weighted mean
value of 88 calculated CFs (i.e., (6 + 2 + 3) samples × 8 measurements). The standard
deviation on all measurements was 1.14, yielding a CoV of 3.6%.
Based on the recommended measurements of 137Cs and 129I standard calibrated
sources, the variability of the well counter sensitivity was evaluated to be less than 1%
over 4 years.
Despite the high constancy of the sensitivity of the well counter over time, the
systematic and random errors committed on activity quantification were estimated at
−12.89 [16.55] % (N = 34) for measurements based on the residual patient activity.
A systematic underestimation (superior to 5%) was observed for activities higher than
100 kBq due to dead-time effect on quantification (Fig. 7).
Discussion
Patient dosimetry offers the possibility of PRRT individualization with the prospect of
improved therapy outcome. Owing that accuracy and precision of the activity measure-
ments are prerequisites to a reliable dosimetry, we have studied the means to obtain
them through the radionuclide calibrator, the SPECT/CT camera and the NaI(Tl) wellFig. 6 Differences, over time and range of activities, between expected and measured activity concentration in
177Lu uniform phantom area on SPECT/CT images. Activity concentrations and activities ranged from 933 to
1 kBq/ml and from 1926 to 0.6 MBq, respectively
Fig. 7 Decay-corrected measured activities in well counter normalized by the mean value for each sample
over range of activities
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define the optimal parameters for activity measurement for 177Lu-DOTATATE PRRT
dosimetry. Home-made calibration sources and phantoms have been prepared using
177Lu, to compute the CF needed to convert measured counts to becquerels for each
device. Finally, dedicated quality control steps have been proposed to evaluate the ac-
curacy and the precision of the established CF for the chosen measurement parameters
with respect to manufacturer maintenance, time, and range of activities. An error of
−0.99 [1.31] % was found for the radionuclide calibrator activity quantification, demon-
strating its high accuracy and precision over time. Therefore, it was considered as the
reference for the preparation of the SPECT/CT camera phantoms and the well counter
sources. The CF was established and controlled using the 2 mL manufacturer vial con-
taining 177LuCl3, however, no control was performed on the 20 mL vial used in clinical
routine for the 177Lu-DOTATATE production. Nonetheless, both vials were located in
the same area of the radionuclide calibrator leading to comparable sensitivity. Besides,
Beauregard et al. [8] have shown a reading difference of less than 0.2% between 177Lu
solutions in syringes and Eppendorf tubes, stating that there was no significant
geometry dependence. Although, the linearity of the CF was not systematically
controlled over an array of 177Lu activities, it still was evaluated by means of a 99mTc
source measured from 30,000 to 0.5 MBq. The error committed on the computed half-
life was 0.33%, and the maximum error on activity quantification was only 5% for the
lowest measured activity (data not shown). This strengthened our confidence in the
activity quantification reliability of the radionuclide calibrator over a range of activities
used in clinical care.
The acquisition and reconstruction parameters for 177Lu SPECT imaging were
studied and established in 2011, based on the paper of Beauregard et al. [8] and on the
phantom measurements presented here. In 2012, the MIRD pamphlet No. 23, related
to the standardization of SPECT imaging for molecular radiotherapy dosimetry, was
published [14]. Although our study preceded this publication, most of our choices were
in accordance to: body contouring, MELP collimator, 128 × 128 matrix with 4.8 mm pixel
size, and total acquisition time of 25 min. The images were acquired in 64 frames of 40 or
80 s with a total acquisition time longer than reported by most patients’ studies [15–17].
On the other hand, to minimize undersampling, the number of frames should have been
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of the exclusive use of the 208 keV energy window. Other groups added the 113 keV
photopeak, however, despite higher counting statistics, they showed that the contamin-
ation of the photopeak by scattered and down-scattered photons complicates the SC,
occasioning increased noise [6, 7]. The OSEM reconstruction algorithm implemented
with 16 iterations and 16 subsets, and a 12-mm FWHM Gaussian filter was also in ac-
cordance with the aforementioned MIRD pamphlet. These parameters offered a good
compromise between noise and resolution and were suitable for clinical review as they
were validated by an expert nuclear medicine physician based on visual image assessment.
For lesion dosimetry, resolution is more critical and reconstruction parameters should
probably be reassessed. Finally, the SC was implemented with the DEW method
with k = 1 and 20 and 10% width for photopeak and scatter windows, respectively. It was
supported by De Nijs et al. [10] who have implemented a similar DEW SC method with
the same photopeak window width but with a scatter window twice as large and half the
previous scaling factor (k = 0.5). For medium energy collimator, they have shown that the
results were quite similar to those obtained with the triple energy window method and
slightly weaker than with a more sophisticated effective scatter source estimation (ESSE)
method [18]. Moreover, in the specific case of the 177Lu spectrum, the number of counts
detected over 228.8 keV is not significant, avoiding the implementation of a triple energy
window SC method based on the use of a third upper scatter window.
The SPECT CF was validated through repeated phantom measurements for activities
and activity concentrations ranging from 7040 to 0.6 MBq and from 933 to 1 kBq/mL,
respectively, over 2.5 years. The mean activity quantification error was −1.05 [2.12] % for
activity concentrations higher than 20 kBq/ml. Consequently, dead time is not an issue for
most centres where 7400 MBq fixed doses are commonly administered. However, PRRT
personalization may require higher injected activities and dead-time problem will have to
be readdressed. On the other hand, the measurement of activity concentrations lower than
20 kBq/ml highlights a systematic activity overestimation varying from a few percent up to
30% for an activity concentration of 1 kBq/mL. This can be a major concern for clinical
applications where quantification is needed in areas of low activity concentration, such as
the red marrow. The origin of the problem remains unclear but initial investigation sug-
gests that a measured background signal could be subtracted to correct for this overesti-
mation. The impact of photomultiplier tuning (during manufacturer maintenance) on
activity quantification was evaluated as well and deemed not significant. Our study
prompts the SPECT/CT camera as a highly reliable tool for activity quantification in PRRT.
Furthermore, it stresses the importance of regularly controlling the constancy of the CF
over time and its validity for activity concentrations encountered in patients’ studies.
Apart from the radionuclide calibrator and the SPECT/CT camera, the NaI(Tl) well
counter is widely used in clinical setting in particular to quantify the activity in blood
samples for bone marrow dosimetry in molecular radiotherapy [19, 20]. Unfortunately,
measurement settings are rarely detailed and few recommendations are found.
Moreover, the validation and practical implementation of relative or absolute calibra-
tion and quality controls are generally not reported. In this study, we have shown that
the well counter was very constant, with less than 1% of variability on the relative
number of counts detected over 4 years. It was measured with 129I and 137Cs standard
calibrated sources as recommended [11].
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proved to be lower than 5% from 0.1 to 100 kBq of 177Lu. Over 100 kBq, count loss
due to dead time becomes significant (Fig. 7). The activity in 200 μL patient blood sam-
ples is typically around 60 kBq just after the injection of 177Lu-DOTATATE. Thus, they
are not impacted by this effect. This well-known dead-time problem and the well coun-
ter high sensitivity have been reported previously by Lodge et al. [21] and were also
mentioned in the user manual. Consequently, for accurate quantification, samples need
to contain an activity lower than 100 kBq. Such activity cannot be directly measured
with any other instrument and has to be prepared by successive dilutions of a source
measured in the radionuclide calibrator, adding in the process possible uncertainties on
the sample activity.
The CoV of 3.6% on samples prepared for the computation of the CF gave high
confidence in the reliability of the CF. However, important systematic and stochas-
tic errors of −12.89 [16.55] % were measured for the samples issued from residual
patient activity and prepared to control the CF. After investigation, it was
concluded that the only significant difference between both cases was the use of
177Lu for the CF determination and of 177Lu-DOTATATE for the CF control. This
hypothesis was further supported by the observation reported here. At the end of
the 177Lu-DOTATATE preparation process, a certain volume of solution was
extracted from the production vial so that the activity left in the vial corresponded
to the intended activity to be injected to the patient. It was regularly observed that
this extracted volume was larger than expected based on the known activity
concentration in the production vial. It can only be the case if 177Lu-DOTATATE
was not homogeneously distributed in the vial, even though the solution was
vortexed during the process. The activity in samples taken from the syringe was
too small to be measured by the radionuclide calibrator. Their activity was thus
computed from the known activity concentration of the syringe, on the assumption
that 177Lu-DOTATATE was homogeneously distributed. This assumption was likely
false, leading to important errors in the activity determination of those samples.
This highlights the importance of controlling every step of the sample preparation
process for the well counter.
Ultimately, the comparison of the relative quantification errors obtained with the
radionuclide calibrator, the SPECT/CT camera and the NaI(Tl) well counter (Fig. 8)
further supports the confidence in the quantification capabilities of 177Lu by the radio-
nuclide calibrator and the SPECT/CT camera. Moreover, by working in the same range
of activities, it allows easy cross-calibration with a unique radioactive source. Due to its
very high sensitivity, the well counter can only be calibrated after dilution or decay of
the aforementioned source or with dedicated calibrated source. Despite this weakness,
the well counter is a very precise measurement tool making wide range of activities
handling possible.
Conclusions
This study proposed critical and dedicated quality control steps related to the quantifi-
cation of the 177Lu activity with a radionuclide calibrator, a SPECT/CT camera and a
NaI(Tl) well counter. The appropriate use of these measuring devices has been
validated in a clinical setting and results in precise and accurate activity quantification.
Fig. 8 Box-and-whisker plot of the differences between the expected and the measured 177Lu activity for
the radionuclide calibrator, the SPECT/CT camera and the NaI(Tl) well counter
Marin et al. EJNMMI Physics  (2017) 4:7 Page 14 of 15Based on these activity measurements, reliable absorbed dose computation can be
developed for 177Lu-based therapy. More importantly, our findings have highlighted the
importance of the knowledge of the strengths and weaknesses of the measuring devices
involved, as well as the errors committed on activity quantification. This information is
indeed of utmost importance to obtain reliable results and should therefore always be
investigated in further developments of dosimetry protocols.
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